Genetic engineering of Lactococcus lactis to produce an amylase inhibitor for development of an anti-diabetes biodrug

被引：0

作者：

D'Souza, Roshan ^{[1
]}

Pandeya, Dipendra Raj ^{[1
]}

Rahman, Mashiar ^{[1
]}

Lee, Hyun Seo ^{[1
]}

Jung, Jin-Kyoung ^{[1
]}

Hong, Seong-Tshool ^{[1
]}

机构：

[1] Chonbuk Natl Univ Sch, Genet Lab, Dept Microbiol & Immunol, Inst Med Sci, Chonju 561712, Chonbuk, South Korea

来源：

NEW MICROBIOLOGICA | 2012年 / 35卷 / 01期

关键词：

Lactococcus lactis; Post prandial hyperglycemia; alpha-amylase inhibitors; EXPRESSION; DESIGN; SYSTEM;

D O I：

暂无

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Diabetes is known as a multifactorial disease. The treatment of diabetes is complicated due to its inherent pathophysiological factors related to the disease. One of the complications of diabetes is postprandial hyperglycemia. Glucosidase inhibitors, particularly alpha-amylase inhibitors can help manage postprandial hyperglycemia. The low molecular weight inhibitor of alpha-amylases called PAMI (peptide amylase inhibitor) inhibits the alpha-amylase. In this study we cloned this amylase blocker PAMI in Lactococcus lactis. Using this Lactococcus lactis expressing the PAMI, we prepared yogurt and fed it to diabetic mice models. There was decrease in the blood glucose level after 20 days of oral administration of the yogurt. This product be used as a biodrug in maintaining the blood glucose level in diabetic patients.

引用

页码：35 / 42

页数：8